| 1 |
CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2019. [EB/OL]. [2020-12-18].
URL
|
| 2 |
胡付品, 朱德妹. 医疗机构碳青霉烯类耐药肠杆菌科细菌感染防控指南简介 [J]. 中国感染与化疗杂志, 2018, 18(3): 331-335.
|
| 3 |
Centers for disease control and prevention. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE) 2015 update [EB/OL]. [2017-07-29].
URL
|
| 4 |
Castanheira M, Deshpande LM, Mendes RE, et al. Variations in the occurrence of resistance phenotypes and Carbapenemase genes among enterobacteriaceae isolates in 20 years of the SENTRY antimicrobial surveillance program [J]. Open Forum Infect Dis, 2019, 6(Suppl1): S23-S33.
|
| 5 |
胡付品, 郭燕, 朱德妹, 等. 2018年CHINET中国细菌耐药性监测 [J]. 中国感染与化疗杂志, 2020, 20(1): 1-10.
|
| 6 |
胡付品, 朱德妹, 汪复, 等. 2015年CHINET细菌耐药性监测 [J]. 中国感染与化疗杂志, 2016, 16(6): 685-694.
|
| 7 |
Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018 [J]. Eur J Clin Microbiol Infect Dis, 2019, 38(12): 2275-2281.
|
| 8 |
Iovleva A, Doi Y. Carbapenem-resistant Enterobacteriaceae [J]. Clin Lab Med, 2017, 37(2): 303-315.
|
| 9 |
胡付品, 郭燕, 朱德妹, 等. 2020年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2021, 21(4): 377-387.
|
| 10 |
Clancy CJ, Potoski, BA, Buehrle D, et al. Estimating the treatment of carbapenem-resistant enterobacteriaceae infections in the United States using antibiotic prescription data [J]. Open Forum Infect Dis, 2019, 6(8): ofz344.
|
| 11 |
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa) [J]. Clin Infect Dis, 2021, 72(7): e169-e183.
|
| 12 |
van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation beta-Lactam/beta-Lactamase Inhibitor Combinations [J]. Clin Infect Dis, 2016, 63(2): 234-41.
|
| 13 |
黄天敏, 杨映霞, 姜赛平, 等. 头孢他啶阿维巴坦的临床应用进展 [J]. 中国新药与临床杂志, 2019, 38(3): 129-134.
|
| 14 |
Han R, Shi Q, Wu S, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant enterobacteriaceae isolated from adult and children patients in China [J]. Front Cell Infect Microbiol, 2020, 10: 314.
|
| 15 |
Ojdana D, Gutowska A, Sacha P, et al. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae [J]. Microb Drug Resist, 2019, 25(9): 1357-1364.
|
| 16 |
Zhang W, Guo Y, Li J, et al. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae [J]. Antimicrob Resist Infect Control, 2018, 7: 142.
|
| 17 |
Das S, Li J, Armstrong J, et al. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects [J]. Pharmacol Res Perspect, 2015, 3(5): e00172.
|
| 18 |
Dimelow R, Wright JG, MacPherson M, et al. Population pharmacokinetic modelling of ceftazidime and avibactam in the plasma and epithelial lining fluid of healthy volunteers [J]. Drugs R D, 2018, 18(3): 221-230.
|
| 19 |
Mosley JF2nd, Smith LL, Parke CK, et al. Ceftazidime-Avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections [J]. P T, 2016, 41(8): 479-483.
|
| 20 |
Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers [J]. Clin Ther, 2015, 37(4): 877-886.
|
| 21 |
Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae Bacteremia [J]. Antimicrob Agents Chemother, 2017, 61(8): e00883-17.
|
| 22 |
Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of Ceftazidime-Avibactam Salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae [J]. Clin Infect Dis, 2019, 68(3): 355-364.
|
| 23 |
Tsolaki V, Mantzarlis K, Mpakalis A, et al. Ceftazidime-Avibactam to treat life-threatening infections by carbapenem-resistant pathogensin critically ill mechanically ventilated patients [J]. Antimicrob Agents Chemother, 2020, 64(3):e02320-19.
|
| 24 |
Tumbarello M, Raffaelli F, Raffaelli F, et al. Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study [J]. Clin Infect Dis, 2021, 73(9): 1664-1676..
|
| 25 |
Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for Ceftazidime-Avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections [J]. Antimicrob Agents Chemother, 2018, 62(5):e02497-17.
|
| 26 |
Shi Y, Hu J, Liu P, et al. Ceftazidime-Avibactam-based versus Tigecycline-based regimen for the treatment of carbapenem-resistant Klebsiella pneumoniae-induced pneumonia in critically ill patients [J]. Infect Dis Ther, 2021, 10(4): 2721-2734.
|
| 27 |
Sousa A, Pérez-Rodríguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae [J]. J Antimicrob Chemother, 2018, 73(11): 3170-3175.
|
| 28 |
Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with Ceftazidime-Avibactam for multidrug-resistant gram-negative bacterial infections [J]. Open Forum Infect Dis, 2019, 6(12): ofz522.
|
| 29 |
Samuel S, Edwards NJ, Rojas LJ, et al. Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae [J]. Open Forum Infect Dis, 2016, 3(Suppl 1): 1182.
|
| 30 |
Gofman N, To K, Whitman M, et al. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin [J]. Am J Health Syst Pharm, 2018, 75(13): 953-957.
|
| 31 |
Yasmin M, Hanrahan J, Hanrahan J, et al. Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with Ceftazidime/Avibactam [J]. Open Forum Infect Dis, 2020, 7(9): ofaa349.
|
| 32 |
Holyk A, Belden V, Lee JJ, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report [J]. J Antimicrob Chemother, 2018, 73(1): 254-256.
|
| 33 |
Parruti G, Frattari A, Polilli E, et al. Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodesdue to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report [J]. J Med Case Rep, 2019, 13(1): 20.
|
| 34 |
Wilson GM, Fitzpatrick M, Walding K, et al. Meta-analysis of clinical outcomes using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the treatment of multidrug-resistant gram-negative infections [J]. Open Forum Infect Dis, 2021, 8(2): ofaa651.
|
| 35 |
Ackley R, Roshdy D, Meredith J, et al. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections [J]. Antimicrob Agents Chemother, 2020, 64(5): e02313-19.
|
| 36 |
King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with Ceftazidime-Avibactam in patients with carbapenem-resistant Enterobacteriaceae infections [J]. Antimicrob Agents Chemother, 2017, 61(7): e00449-17.
|
| 37 |
Fiore M, Alfieri A, Di Franco S, et al. Ceftazidime-Avibactam combination therapy compared to Ceftazidime-Avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis [J]. Antibiotics (Basel), 2020, 9(7): 388.
|
| 38 |
Onorato L, Di Caprio G, Signoriello S, et al. Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis [J]. Int J Antimicrob Agents, 2019, 54(6): 735-740.
|
| 39 |
Cheng K, Newell P, Chow JW, et al. Safety profile of Ceftazidime-Avibactam: pooled data from the adult phase Ⅱ and phase Ⅲ clinical trial programme [J]. Drug Saf, 2020, 43(8): 751-766.
|
| 40 |
Zhang H, Xu Y, Xu Y, et al. Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016) [J]. Antimicrob Resist Infect Control, 2020, 9(1): 166.
|
| 41 |
Shields RK, Nguyen MH, Press EG, et al. Emergence of Ceftazidime-Avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing kpneumoniae: a case report and review of literature [J]. Open Forum Infect Dis, 2017, 4(3): ofx101.
|
| 42 |
Shi Q, Yin D, Yin D, et al. Emergence and recovery of Ceftazidime-avibactam resistance in blaKPC-33-Harboring Klebsiella pneumoniae sequence type 11 isolates in China [J]. Clin Infect Dis, 2020, 71(Suppl 4): S436-S439.
|
| 43 |
Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime-avibactam and underlying mechanisms [J]. J Glob Antimicrob Resist, 2020, 22: 18-27.
|